Who
Brett P. Monia
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Ionis Pharmaceuticals; Director, Cognition Therapeutics.
In numbers
- Trades disclosed
- 360
- Buys
- 0
- Sells
- 73
- Bought
- $0
- Sold
- $98.1M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Jan 2012
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $5,02898 at $51.31 | filing |
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $5,02898 at $51.31 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.8M50,000 at $56.78 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4.0M50,000 at $80.59 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.8M50,000 at $56.78 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4.0M50,000 at $80.59 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $687K21,072 at $32.60 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,072 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.7M21,072 at $78.49 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,072 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $687K21,072 at $32.60 | filing |
| 25 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.7M21,072 at $78.49 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $475K14,565 at $32.60 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M14,565 at $78.41 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,565 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,565 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $475K14,565 at $32.60 | filing |
| 24 Jun 2026filed 26 Jun 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M14,565 at $78.41 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Brett P. Monia; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.